AbbVie Inc (ABBV) - Rapport boursier

AbbVie sells branded prescription medicines for serious diseases, plus medical aesthetics products. Its direct customers are wholesalers, distributors, hospitals, specialty pharmacies, government agencies, and some doctors, who buy on behalf of patients, insurers, and other healthcare payers. AbbVie earns money by discovering a medicine, proving it works in hard-to-treat conditions, winning doctor and insurer adoption, and then supplying it for years. A few large products carry most of the revenue. Each one commands strong prices until its patent protection ends and cheaper copies enter, which is when its sales fall. So the business depends on having newer medicines ready to replace the older ones.

In the second quarter of fiscal 2026, Skyrizi brought in about $5.5 billion and Rinvoq about $2.5 billion, while Humira, the former top seller, fell to $756 million. This matters because it shows AbbVie can replace an aging blockbuster even after cheaper copies of biologic medicines arrive, the moment that usually hurts a drugmaker most.

In June 2026 AbbVie agreed to buy Apogee Therapeutics for about $10.9 billion and keeps spending heavily on research. That commits large sums to medicines not yet approved, so the open question is whether they arrive in time to replace today's winners before those winners age.